Trial Profile
A Multi Center, Prospective, Non Interventional (NI) Study of the Safety and Efficacy of Sunitinib in Chinese Patients With Progressive Advanced or Metastatic Well Differentiated Unresectable Pancreatic Neuroendocrine Tumors
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 29 Mar 2023
Price :
$35
*
At a glance
- Drugs Sunitinib (Primary)
- Indications Neuroendocrine tumours; Pancreatic cancer
- Focus Adverse reactions
- Sponsors Pfizer
- 18 Jan 2023 Status changed from active, no longer recruiting to completed.
- 19 Oct 2021 Status changed from recruiting to active, no longer recruiting.
- 12 Jan 2018 Planned End Date changed from 1 Dec 2022 to 12 Dec 2022.